6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
A deep-dive into REDUCE-IT's randomization, blinding, mineral oil placebo debate, endpoint adjudication, and statistical hierarchy, explaining how each design choice shapes interpretation of icosapent ethyl's 25% MACE reduction.
Deep-dive into cost-effectiveness analyses from the REDUCE-IT trial of icosapent ethyl (Vascepa), including cost per QALY, payer coverage, list vs net pricing, and value for individual patients.
Deep dive into REDUCE-IT follow-up analyses, durability of icosapent ethyl's cardiovascular benefit, post-trial safety signals, and what long-term data reveal beyond the original 4.9-year median.
Complete breakdown of the REDUCE-IT trial results for icosapent ethyl, including primary and secondary MACE endpoints, hazard ratios with confidence intervals, Kaplan-Meier time-course data, and prespecified subgroup analyses.
Deep-dive into REDUCE-IT pre-specified and post-hoc subgroup analyses for icosapent ethyl (Vascepa), examining differential MACE reduction by age, sex, BMI, baseline triglycerides, race, and other clinical variables.
A plain-English deep dive into the REDUCE-IT trial: the methodology, enrollment criteria, mineral oil controversy, full results tables, and what the 25% MACE reduction means for statin-treated patients with elevated triglycerides today.